PDF herunterladen
Synlett 2013; 24(15): 1968-1972
DOI: 10.1055/s-0033-1339465
letter
© Georg Thieme Verlag Stuttgart · New York

A Remarkable One-Pot Sequential Four-Component Synthesis of Tetrahydroquinazolines via an Isocyanide-Based Multicomponent Reaction

Ahmad Shaabani*
a   Faculty of Chemistry, Shahid Beheshti University, G. C., P. O. Box 19396-4716, Tehran, Iran   Fax: +98(21)29903247    eMail: a-shaabani@sbu.ac.ir
,
Mojtaba Mahyari
a   Faculty of Chemistry, Shahid Beheshti University, G. C., P. O. Box 19396-4716, Tehran, Iran   Fax: +98(21)29903247    eMail: a-shaabani@sbu.ac.ir
,
Morteza Aghaei
a   Faculty of Chemistry, Shahid Beheshti University, G. C., P. O. Box 19396-4716, Tehran, Iran   Fax: +98(21)29903247    eMail: a-shaabani@sbu.ac.ir
,
Sajjad Keshipour
a   Faculty of Chemistry, Shahid Beheshti University, G. C., P. O. Box 19396-4716, Tehran, Iran   Fax: +98(21)29903247    eMail: a-shaabani@sbu.ac.ir
,
Seik Weng Ng
b   Department of Chemistry, University of Malaya, 50603, Kuala Lumpur, Malaysia
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received: 16. April 2013

Accepted after revision: 21. Juni 2013

Publikationsdatum:
07. August 2013 (online)

    Lizenzen und Reprints Alle Artikel dieser Rubrik


Abstract

A novel one-pot sequential four-component strategy has been developed for the synthesis of tetrahydroquinazolines using either an aliphatic or an acyl halide, an isocyanide, and a 1,3-diamine, in methanol at 60 °C, in good to moderate yields without using a catalyst.

Key words

quinazoline - multicomponent - isocyanide
 

  • References and Notes

  • 1 Jiang JB, Hesson D, Dusak B, Dexter D, Kang G, Hamel E. J. Med. Chem. 1990; 33: 1721
    Crossref
  • 2 Yale HJ, Kalkstein M. J. Med. Chem. 1967; 10: 334
    Crossref
  • 3 Neil GL, Li LH, Buskirk HH. Cancer Chemother. Pharmacol. 1972; 56: 163
  • 4 Hamel E, Lin CM, Plowman J, Wang HK, Lee KH, Paull KD. Biochem. Pharmacol. 1996; 51: 53
    Crossref
  • 5 Tiwari AK, Mishra AK, Bajpai A, Mishra P, Sharma RK, Pandey VK, Singh VK. Bioorg. Med. Chem. Lett. 2006; 16: 4581
    Crossref
  • 6 Ram VJ, Tripathi BK, Srivastava AK. Bioorg. Med. Chem. 2003; 11: 2439
    CrossrefPubMed
  • 7 Witt A, Bergman J. Curr. Org. Chem. 2003; 7: 659
    Crossref
  • 8 Touroutoglou N, Pazdur R. Clin. Cancer Res. 1996; 2: 227
  • 9 Jackman AL, Harrap KR, Boyle FT. Invest. New Drugs 1996; 14: 305
    Crossref
  • 10 Sielecki TM, Johnson TL, Liu J, Muckelbauer JK, Grafstrom RH, Cox S, Boylan J, Burton CR, Chen H, Smallwood A, Chang C.-H, Boisclair M, Benfield PA, Trainor GL, Seitz SP. Bioorg. Med. Chem. Lett. 2001; 11: 1157
    Crossref
  • 11 Bonomi PE. Expert Opin. Invest. Drugs 2003; 1395
  • 12 Alaimo RJ, Russell HE. J. Med. Chem. 1972; 15: 335
    Crossref
  • 13 Cooper ER. A, Jackson H. J. Reprod. Fertil. 1973; 34: 445
  • 14 Kuo SC, Lee HZ, Juang JP, Lin YT, Wu TS, Chang JJ, Lednicer D, Paull KD, Lin CM. J. Med. Chem. 1993; 36: 1146
    Crossref
  • 15 Lin CM, Kang G, Roach M, Jiang J, Hesson D, Luduena R, Hamel E. Mol. Pharmacol. 1991; 40: 827
  • 16 Hour MJ, Huang LJ, Kuo SC, Xia Y, Bastow K, Nakanishi Y, Hamel E, Lee KH. J. Med. Chem. 2000; 43: 4479
    Crossref
  • 17 Coskun N. Tetrahedron Lett. 2004; 45: 8973
    Crossref
  • 18 Csütörtöki R, Szatmári I, Koch A, Heydenreich M, Kleinpeter E, Fülöp F. Tetrahedron 2011; 67: 8564
    Crossref
  • 19 Balakumar C, Lamba P, Pran Kishore D, Lakshmi Narayana B, Venkat Rao K, Rajwinder K, Raghuram Rao A, Shireesha B, Narsaiah B. Eur. J. Med. Chem. 2010; 4904
  • 20 Bienayme H, Hulme C, Oddon G, Schmitt P. Chem. Eur. J. 2000; 6: 3321
    Crossref
  • 21 Weber L. Curr. Med. Chem. 2002; 9: 1241
  • 22 Schreiber SL. Science 2000; 287: 1964
    CrossrefPubMed
  • 23 Dömling A. Chem. Rev. 2006; 106: 17
    Crossref
  • 24 Orru RV, De Greef M. Synthesis 2003; 1471
    Artikel in Thieme Connect
  • 25 Bienayme H, Hulme C, Oddon G, Schmitt P. Chem. Eur. J. 2000; 6: 3321
    Crossref
  • 26 Zhu J, Bienayme H. Multicomponent Reactions . Wiley-VCH; Weinheim: 2005
    CrossrefGoogle Scholar
  • 27 Shaabani A, Maleki A, Mofakham H, Moghimi-Rad J. J. Org. Chem. 2008; 73: 3925
    Crossref
  • 28 Shaabani A, Rezayan AH, Keshipour S, Sarvary A, Ng SW. Org. Lett. 2009; 11: 3342
    Crossref
  • 29 Shaabani A, Maleki A, Hajishaabanha F, Mofakham H, Seyyedhamzeh M, Mahyari M, Ng SW. J. Comb. Chem. 2009; 12: 186
  • 30 Keshipour S, Shojaei S, Shaabani A. Tetrahedron 2012; 68: 6141
    Crossref
  • 31 Ghadari R, Hajishaabanha F, Mahyari M, Shaabani A, Khavasi HR. Tetrahedron Lett. 2012; 53: 4018
    Crossref
  • 32 Shaabani A, Keshipour S, Shaabani S, Mahyari M. Tetrahedron Lett. 2012; 53: 1641
    Crossref
  • 33 Nef JU. Justus Liebigs Ann. Chem. 1892; 270: 267
    Crossref
  • 34 Coffinier D, El Kaim L, Grimaud L. Org. Lett. 2009; 11: 1825
    Crossref
  • 35 El Kaim E, Grimaud L, Wagschal S. Synlett 2009; 1315
    Artikel in Thieme Connect
  • 36 Mossetti R, Pirali T, Tron GC, Zhu J. Org. Lett. 2010; 12: 820
    Crossref
  • 37 Coffinier D, El Kaim L, Grimaud L. Synlett 2010; 2474
    Artikel in Thieme Connect
  • 38 El Kaim L, Grimaud L, Patil P. Org. Lett. 2011; 13: 1261
    CrossrefPubMed
  • 39 Walborsky H, Niznik G. J. Org. Chem. 1972; 37: 187
    Crossref
    • 40a Azuaje J, Coelho A, Maatougui AE, Blanco JM, Sotelo E. ACS Comb. Sci. 2011; 13: 89
      Crossref
    • 40b Lim YY, Stei AR. Can. J. Chem. 1971; 49: 2455
      Crossref
    • 40c Gassman PG, Haberman LM. Tetrahedron Lett. 1985; 26: 4971
      Crossref
    • 40d Priestley ES, Decicco CP. Org. Lett. 2000; 2: 3095
      Crossref
  • 41 N-Cyclohexyl-4-oxo-2-phenyl-1,2,3,4-tetrahydro-quinazoline-2-carboxamide (4a) – Typical Procedure To magnetically stirred benzoyl chloride (0.14 g, 1.00 mmol) was added cyclohexyl isocyanide (0.11 g, 1.00 mmol), and the reaction mixture was heated for 2 h at 60 °C. After cooling, MeOH (5 mL) and 2-aminobenzamide were added, and the reaction mixture was stirred for 24 h at 60 °C. After completion of the reaction (TLC), the solvent was removed under vacuum, the residue was crystallized from CH2Cl2–n-hexane (3:1), and the product 4a was obtained as a white solid (0.21 g, 60%); yield 0.21 g (60%); mp 222–225 °C. IR (KBr): 3381, 3324, 2932, 2844, 1649, 1612, 1492, 1461 cm–1. 1H NMR (300.13 MHz, DMSO-d 6): δ = 1.08–1.59 (10 H, m, 5 CH2 of c-Hex), 3.52 (1 H, br s, CH of c-Hex), 6.69 (1 H, br s, NH), 6.93 (1 H, br s, NH), 7.25–7.70 (9 H, m, CHAr), 8.41 (1 H, br s, CONH). 13C NMR (75.47 MHz, DMSO-d 6): δ = 24.6, 25.5, 32.4, 48.8, 75.5, 114.7, 115.5, 118.2, 126.8, 127.6, 128.7, 129.0, 134.0, 141.4, 147.2, 163.9, 170.3. MS: m/z (%) = 350 (90) [M+ + 1], 223 (100), 297 (25), 145 (15), 119 (30), 92 (60), 55 (65). Anal. Calcd for C21H23N3O2: C, 72.18; H, 6.63; N, 12.03. Found: C, 72.10; H, 6.58; N, 12.17. 2-(4-Bromophenyl)-N-cyclohexyl-4-oxo-1,2,3,4-tetrahydroquinazoline-2-carboxamide (4b) Yellow powder; yield 0.23 g (54%); mp 242–245 °C. IR (KBr): 3371, 3326, 2922, 2830, 1659, 1622, 1483, 1454 cm–1. 1H NMR (300.13 MHz, DMSO-d 6): δ = 1.14–1.60 (10 H, m, 5 CH2 of c-Hex), 3.50 (1 H, br s, CH of c-Hex), 6.69 (1 H, br s, NH), 6.92 (1 H, br s, NH), 7.28–7.79 (8 H, m, CHAr), 8.53 (1 H, br, CONH). 13C NMR (75.47 MHz, DMSO-d 6): δ = 24.7, 24.8, 32.3, 48.9, 75.1, 114.7, 115.6, 118.3, 122.4, 127.6, 129.1, 129.3, 131.6, 131.8, 134.1, 140.9, 147.0, 163.8, 169.8. Anal. Calcd for C21H22BrN3O2: C, 58.89; H, 5.18; Br, 18.66; N, 9.81. Found: C, 58.75; H, 5.24; N, 9.96. N-Cyclohexyl-2-methyl-4-oxo-1,2,3,4-tetrahydroquinazoline-2-carboxamide (4c) White powder; yield 0.18 g (63%); mp 232–235 °C. IR (KBr): 3413, 3321, 3002, 2923, 2852, 1624, 1580, 1525, 1455 cm–1. 1H NMR (300.13 MHz, DMSO-d 6): δ = 1.07–1.70 (10 H, m, 5 CH2 of c-Hex), 1.88 (3 H, s, CH3), 2.89 (1 H, br s, CH of c-Hex), 7.21 (1 H, br s, NH), 7.38 (1 H, br s, NH), 7.55–7.90 (4 H, m, CHAr), 8.60 (1 H, br, CONH). 13C NMR (75.47 MHz, DMSO-d 6): δ = 24.2, 25.0, 25.2, 30.7, 49.7, 78.1, 115.1, 122.3, 124.8, 126.3, 126.8, 128.1, 135.1, 147.4, 155.4, 164.3. Anal. Calcd for C16H21N3O2: C, 66.88; H, 7.37; N, 14.62. Found: C, 66.80; H, 7.43; N, 14.69. N-tert-Butyl-4-oxo-2-phenyl-1,2,3,4-tetrahydroquinazoline-2-carboxamide (4d) White powder; yield 0.20 g (62%); mp 182–184 °C. IR (KBr): 3260, 3191, 2964, 2926, 2837, 1635, 1612, 1511 cm–1. 1H NMR (300.13 MHz, DMSO-d 6): δ = 1.57 (9 H, s, 3 CH3), 6.62 (1 H, br s, NH), 6.65 (1 H, br s, NH), 6.74–7.33 (9 H, m, Ar), 7.89 (1 H, br, CONH). 13C NMR (75.47 MHz, DMSO-d 6): δ = 29.7, 45.7, 80.1, 114.7, 116.2, 118.7, 126.4, 127.3 128.3, 129.1, 133.9, 134.0, 141.0, 154.0, 164.5. Anal. Calcd for C19H21N3O2: C, 70.57; H, 6.55; N, 12.99. Found: C, 70.64; H, 6.61; N, 12.90. N-Cyclohexyl-2-ethyl-4-oxo-1,2,3,4-tetrahydroquinazoline-2-carboxamide (4e) White powder; yield 0.19 g (63%); mp 176–179 °C. IR (KBr): 2983, 2940, 2862, 2825, 1701, 1644, 1618, 1498, 1455 cm–1. 1H NMR (300.13 MHz, DMSO-d 6): δ = 1.08–1.88 (13 H, m, 5 CH2 of c-Hex and CH3), 2.28 (2 H, br, CH 2CH3), 2.90 (1 H, br s, CH of c-Hex), 7.11 (1 H, br s, NH), 7.19 (1 H, br s, NH), 7.36–7.91 (4 H, m, CHAr), 8.55 (1 H, br, CONH). 13C NMR (62.83 MHz, DMSO-d 6): δ = 23.2, 24.7, 25.4, 32.9, 35.2, 48.4, 76.4, 113.9, 114.1, 117.3, 126.9, 131.8, 148.5, 159.2, 167.1. Anal. Calcd for C17H23N3O2: C, 67.75; H, 7.69; N, 13.94. Found: C, 67.69; H, 7.62; N, 14.09. N-tert-Butyl-2-ethyl-4-oxo-1,2,3,4-tetrahydroquinazoline-2-carboxamide (4f) Brown powder; yield 0.18 g (65%); mp 157–159 °C. IR (KBr): 3259, 2968, 2895, 1634, 1613, 1515, 1492, 1385 cm–1. 1H NMR (300.13 MHz, DMSO-d 6): δ = 1.22–1.33 (14 H, br s, 3 CH3 of t-Bu, CH2CH 3 and CH 2CH3), 6.59 (1 H, br s, NH), 6.67 (1 H, br s, NH), 7.17–7.91 (4 H, m, CHAr), 8.10 (1 H, br, CONH). 13C NMR (75.47 MHz, DMSO-d 6): δ = 27.5, 29.4, 51.4, 67.3, 78.4, 114.2, 114.7, 116.8, 127.6, 133.6, 147.6, 158.4, 168.4. MS: m/z (%) = 276 (25) [M+ + 1], 223 (80), 200 (15), 177 (15), 161 (100), 120 (25), 92 (25), 58 (75). Anal. Calcd for C15H21N3O2: C, 65.43; H, 7.69; N, 15.26. Found: C, 65.49; H, 7.74; N, 15.18. N-Cyclohexyl-2-phenyl-1,2,3,4-tetrahydroquinazoline-2-carboxamide (4g) White powder; yield 0.22 g (66%); mp 153–159 °C. IR (KBr): 2940, 2862, 2730, 1675, 1606, 1511, 1442 cm–1. 1H NMR (300.13 MHz, DMSO-d 6): δ = 1.07–1.89 (10 H, m, 5 CH2 of c-Hex), 2.88 (2 H, br, CH2, ArCH2), 3.40 (1 H, br s, CH of c-Hex), 6.63 (1 H, br s, NH), 6.72 (1 H, br s, NH), 7.14–7.24 (9 H, m, Ar), 8.35 (1 H, br, CONH). 13C NMR (75.47 MHz, DMSO-d 6): δ = 24.2, 25.0, 30.6, 41.1, 49.7, 76.6, 117.2, 118.4, 127.4, 126.2, 127.5, 127.6, 128.5, 129.2, 131.3, 150.1, 151.2, 167.9. Anal. Calcd for C21H25N3O: C, 75.19; H, 7.51; N, 12.53. Found: C, 75.12; H, 7.44; N, 12.62. N-Cyclohexyl-2-methyl-1,2,3,4-tetrahydroquinazoline-2-carboxamide (4h) White powder; yield 0.19 g (70%); mp 145–148 °C. IR (KBr): 3425, 3336, 3021, 2936, 1637, 1587, 1500, 1461 cm–1. 1H NMR (300.13 MHz, DMSO-d 6): δ = 1.07–1.70 (10 H, m, 5 CH2 of c-Hex), 1.89 (3 H, s, CH3), 2.89 (1 H, br s, CH of c-Hex), 3.86 (2 H, br, CH2, ArCH2), 6.56 (1 H, br s, NH), 6.69 (1 H, br s, NH), 7.01–7.15 (4 H, m, CHAr), 8.26 (1 H, br, CONH). 13C NMR (75.47 MHz, DMSO-d 6): δ = 24.2, 25.0, 30.7, 38.9, 40.9, 49.7, 82.2, 116.0, 116.6, 117.7, 129.8, 130.9, 147.5, 159.1, 165.2. Anal. Calcd for C16H23N3O: C, 70.30; H, 8.48; N, 15.37. Found: C, 70.39; H, 8.57; N, 15.24. N-Cyclohexyl-2-ethyl-1,2,3,4-tetrahydroquinazoline-2-carboxamide (4i) White powder; yield 0.19 g (66%); mp 149–151 °C. IR (KBr): 3381, 3325, 3014, 2932, 2869, 1648, 1612, 1503 cm–1. 1H NMR (300.13 MHz, DMSO-d 6): δ = 0.84–1.67 (13 H, m, 5 CH2 of c-Hex and CH3), 1.89 (2 H, br s, CH 2CH3), 2.88 (1 H, br s, CH of c-Hex), 3.39 (2 H, br, ArCH2), 6.56 (1 H, br s, NH), 6.70 (1 H, br s, NH), 7.13–7.28 (4 H, m, CHAr), 8.20 (1 H, br, CONH2). 13C NMR (75.47 MHz, DMSO-d 6): δ = 15.6, 24.2, 25.0, 30.6, 40.7, 41.1, 49.7, 77.3, 117.2, 118.4, 127.4, 127.6, 129.3, 131.3, 150.1, 157.3, 164.5. Anal. Calcd for C17H25N3O: C, 71.04; H, 8.77; N, 14.62. Found: C, 71.21; H, 8.64; N, 14.70. (2E,2′E)-2,2′-[Ethane-1,2-diylbis(azan-1-yl-1-ylidene)]bis[2-(4-bromophenyl)-N-cyclohexylacetamide] (8) White powder; yield 0.50 g (78%); mp 202–204 °C. IR (KBr): 3244, 3071, 2093, 2853, 1623, 1553, 1448 cm–1. 1H NMR (300.13 MHz, DMSO-d 6): δ = 1.22–1.84 (20 H, m, 10 CH2 of c-Hex), 2.15–2.21 (4 H, m, 2 CH2), 3.10 (2 H, br s, 2 NH), 3.64–3.75 (2 H, m, 2 CH of c-Hex), 7.16–7.60 (10 H, m, CHAr), 7.74 (2 H, br, CONH). 13C NMR (75.47 MHz, DMSO-d 6): δ = 24.8, 25.5, 32.8, 46.1, 84.6, 125.6, 128.2, 128.4, 141.8, 172.9. MS: m/z = 646 (10) [M+ + 2], 644 (20) [M+], 642 (10) [M+ – 2], 604 (15), 518 (50), 478 (25), 392 (15), 351 (20), 335 (30), 321 (10), 266 (20), 210 (25), 184 (60), 102 (15), 83 (70), 55 (100). Anal. Calcd for C28H38N4, C, 78.10; H, 8.89; N, 13.01. Found: C, 78.01; H, 8.95; N, 13.05. (2E,2′E)-2,2′-[1,2-Phenylenebis(azan-1-yl-1-ylidene)]bis[2-(4-bromophenyl)-N-cyclohexylacetamide] (9) White powder; yield 0.49 g (71%); mp 162–163 °C. IR (KBr): 3338, 3297, 2933, 2878, 2854, 1644, 1514, 1485, 1455 cm–1. 1H NMR (300.13 MHz, DMSO-d 6): δ = 1.24–1.83 (20 H, m, 10 CH2 of c-Hex), 2.82 (4 H, br, 2 CH2), 3.64 (2 H, br s, 2 CH of c-Hex), 7.49–7.66 (8 H, m, CHAr), 7.72 (2 H, br, CONH). 13C NMR (75.47 MHz, DMSO-d 6): δ = 25.0, 25.5, 32.7, 46.6, 48.0, 84.5, 123.0, 128.8, 129.9, 131.0, 175.2. Anal. Calcd for C28H36Br2N4, C, 57.15; H, 6.17; Br, 27.16; N, 9.52. Found: C, 57.10; H, 6.09; N, 9.61.